Peter Kaiser, MD

Appointed
1997

Education & Fellowships

Fellowship - Bascom Palmer Eye Institute-Anne Bates Leach Eye Hospital
Ophthalmology
Miami, FL USA
1997

Residency - Massachusetts Eye and Ear Infirmary
Ophthalmology
Boston, MA USA
1996

Internship - Massachusetts General Hospital
Internal Medicine
Boston, MA USA
1993

Medical Education - Harvard Medical School
Boston, MA USA
1992

Undergraduate - Harvard University
Biology
Cambridge, MA USA
1988

Additional Training

• FELLOWSHIP: Bascom Palmer Eye Institute
  • Miami Florida
  • Medical retina and vitreoretinal surgery  1996-1997
  • RESIDENCY:Massachusetts Eye and Ear Infirmary 1993-1996
    • Boston, MA
    • Ophthalmology
    • INTERNSHIP:Massachusetts General Hospital 1992-1993
      • Boston MA
      • Internal Medicine
      • MEDICAL SCHOOL:Harvard Medical School 1988-1992
        • Boston MA
        • Doctor of Medicine
        • COLLEGE: Harvard College 1984-1988
          • Boston MA
          • Bachelor of Arts

      Professional Highlights

      • Editor-in-Chief, Current Concepts in Retina
      • Founding Director, Digital OCT Reading Center (DOCTR)
      • Associate Editor, American Journal of Ophthalmology
      • Editorial board, Retina, Retina Today, Retinal Physician, Ocular Surgery News
      • Associate Editor,  International Ophthalmology Clinics

      Certifications

      • Ophthalmology

      Specialty Interests

      Epiretinal membranes, vitreomacular traction, macular holes, age-related macular degeneration, Diabetic retinopathy, Retinal Detachment, vitreoretinal diseases

      Awards & Honors

      • American Academy of Ophthalmology Senior Achievement Award (Senior Honor Award), 2008
      • National Institute of Health, RO1 grant funding, 2005-present
      • Who's Who in Executives and Professionals Listing National Register, West Islip NY, 2004- present
      • American Society of Retina Specialists, Senior Achievement Award (Senior Honor Award), 2003
      • American Society of Retina Specialists, Achievement Award (Honor Award), 2002
      • Best Doctors in America listing, 2002 - present
      • Best Doctors in Midwest listing, 2002-present
      • Best Doctors in Cleveland listing, 2002-present
      • American Academy of Ophthalmology Achievement Award (Honor Award), 2001
      • Strathmore's Who's Who listing, 2000-present
      • Study Chairman, DENALI Phase 3 Study
      • Study Chairman, VERITAS Phase 3 Study
      • Study Chairman, VIO Phase 3 Study
      • Study Chairman, TargeGen Phase 1 Study

      Innovations & Patents

      • Pioneer in the use of, and developer of several new 23 gauge surgical techniques, which allow sutureless vitrectomy surgery with less pain and faster visual recovery or patients
      • Pioneer in new vitrectomy systems that offer better flow rates, faster cutting speeds, and safer probes than current machines
      • First MD to use a modified RNA interfering molecule to treat age-related macular degeneration; this technique and its technology was the first time it had been used in any disease after the discovery of RNAi received the Nobel Prize in Medicine
      • Pioneer in the use of spectral domain optical coherence tomography in the diagnosis and management of vitreoretinal diseases

      Memberships

      • Retina Society, 2003- present
      • Pan-American Ophthalmology Association, 2000- present
      • American Society of Retina Specialists (Vitreous Society), 2000 - present
      • Cleveland Ophthalmological Society, 1997 - present
      • International Academy of Sports Vision, 1997 - present

See publications for Peter Kaiser, MD.

(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 8/3/2023, Dr. Kaiser has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Consulting and/or Speaking. Dr. Kaiser receives fees of $5,000 or more per year (or, in rare cases, equity or stock options) as a paid consultant, speaker or as a member of an advisory committee for the following companies:

• Coherus BioSciences
• Aviceda Therapeutics
• Clearside Biomedical, Inc
• Novartis International, AG
• Genentech, Inc
• Bausch and Lomb
• Thea Laboratories
• Merck Sharp & Dohme
• Ocular Therapeutix, Inc.
• Iveric bio, Inc.
• Annexon Biosciences, Inc.
• Allergan Sales, LLC
• RegenexBio, Inc.
• Boehringer Ingelheim
• Bayer AG
• Regeneron Pharmaceuticals, Inc.
• Biogen Idec, Inc.
• Ocuphire Pharma, Inc.

Donation of Financial Interest. Dr. Kaiser has consulted for, received compensation for serving as a fiduciary from, or received royalties from the following companies but instructed them to donate all compensation to not-for-profit causes or to the Cleveland Clinic to support research and education:

• Stealth BioTherapeutics Incorporated

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.